(Q34070913)

30 July 2017

1 reference

title

Continuous dopamine-receptor stimulation in advanced Parkinson's disease (English)

1 reference

30 July 2017

0 references

1 reference

Nutt JG

1

1 reference

30 July 2017

Obeso JA

series ordinal

2

1 reference

30 July 2017

Stocchi F

series ordinal

3

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

published in

Trends in Neurosciences

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

10 Suppl

1 reference

30 July 2017

page(s)

S109-15

1 reference

Levodopa motor complications in Parkinson's disease

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Relations between movement and single cell discharge in the substantia nigra of the behaving monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Substantia nigra dopaminergic unit activity in behaving cats: effect of arousal on spontaneous discharge and sensory evoked activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Responses of monkey dopamine neurons during learning of behavioral reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Firing properties of substantia nigra dopaminergic neurons in freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Volume transmission in the CNS and its relevance for neuropsychopharmacology.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Evidence for striatal dopamine release during a video game

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Dystonia with marked diurnal variation associated with biopterin deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Behavioral correlates of dopaminergic unit activity in freely moving cats

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Exercise and the antiparkinsonian response to levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Dopamine-receptor stimulation: biobehavioral and biochemical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Timing of levodopa therapy: evidence from MPTP-treated primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Short- and long-duration responses to levodopa during the first year of levodopa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

1 reference

7 January 2021

Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Motor response following repeated apomorphine administration is reduced in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Time course of tolerance to apomorphine in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

A 10-year follow-up--genotypic analysis disproves phenotypic classification

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900029-X

7 January 2021

10.1016/S1471-1931(00)00029-X

Identifiers

DOI

1 reference

30 July 2017

1 reference